Radiotherapy and theranostics: a Lancet Oncology Commission
May Abdel-Wahab,Francesco Giammarile,Mauro Carrara,Diana Paez,Hedvig Hricak,Nayyereh Ayati,Jing Jing Li,Malina Mueller,Ajay Aggarwal,Akram Al-Ibraheem,Sondos Alkhatib,Rifat Atun,Abubakar Bello,Daniel Berger,Roberto C Delgado Bolton,John M Buatti,Graeme Burt,Olivera Ciraj Bjelac,Lisbeth Cordero-Mendez,Manjit Dosanjh,Thomas Eichler,Elena Fidarova,Soehartati Gondhowiardjo,Mary Gospodarowicz,Surbhi Grover,Varsha Hande,Ekaterina Harsdorf-Enderndorf,Ken Herrmann,Michael S Hofman,Ola Holmberg,David Jaffray,Peter Knoll,Jolanta Kunikowska,Jason S Lewis,Yolande Lievens,Miriam Mikhail-Lette,Dennis Ostwald,Jatinder R Palta,Platon Peristeris,Arthur A Rosa,Soha Ahmed Salem,Marcos A Dos Santos,Mike M Sathekge,Shyam Kishore Shrivastava,Egor Titovich,Jean-Luc Urbain,Verna Vanderpuye,Richard L Wahl,Jennifer S Yu,Mohamed Saad Zaghloul,Hongcheng Zhu,Andrew M Scott
DOI: https://doi.org/10.1016/S1470-2045(24)00407-8
Abstract:Following on from the 2015 Lancet Oncology Commission on expanding global access to radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created to assess the access and availability of radiotherapy to date and to address the important issue of access to the promising field of theranostics at a global level. A marked disparity in the availability of radiotherapy machines between high-income countries and low-income and middle-income countries (LMICs) has been identified previously and remains a major problem. The availability of a suitably trained and credentialled workforce has also been highlighted as a major limiting factor to effective implementation of radiotherapy, particularly in LMICs. We investigated initiatives that could mitigate these issues in radiotherapy, such as extended treatment hours, hypofractionation protocols, and new technologies. The broad implementation of hypofractionation techniques compared with conventional radiotherapy in prostate cancer and breast cancer was projected to provide radiotherapy for an additional 2·2 million patients (0·8 million patients with prostate cancer and 1·4 million patients with breast cancer) with existing resources, highlighting the importance of implementing new technologies in LMICs. A global survey undertaken for this Commission revealed that use of radiopharmaceutical therapy-other than 131I-was highly variable in high-income countries and LMICs, with supply chains, workforces, and regulatory issues affecting access and availability. The capacity for radioisotope production was highlighted as a key issue, and training and credentialling of health professionals involved in theranostics is required to ensure equitable access and availability for patient treatment. New initiatives-such as the International Atomic Energy Agency's Rays of Hope programme-and interest by international development banks in investing in radiotherapy should be supported by health-care systems and governments, and extended to accelerate the momentum generated by recognising global disparities in access to radiotherapy. In this Commission, we propose actions and investments that could enhance access to radiotherapy and theranostics worldwide, particularly in LMICs, to realise health and economic benefits and reduce the burden of cancer by accessing these treatments.